In this age of rapid change, we strive to deliver the world’s best solutions to global challenges in the fields of health and nutrition.
With life expectancy continuing to rise, we improve quality of life for a growing population by focusing our research and development activities on preventing, alleviating and treating diseases. We are also making an important contribution to providing a reliable supply of high-quality food, feed and plant-based raw materials.
In Canada, we have over 1,400 passionate and innovative employees. As a Life Science company we have three divisions – Pharmaceuticals, Consumer Health and Crop Science – and the Radiology business unit. We are committed to operating sustainably and addressing our social and ethical responsibilities. As we continue to shape our industry, our efforts are catalyzed by focusing on our customers. All of this makes up our corporate purpose: Science for a better life.
Finerenone significantly reduced renal and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes
• Finerenone is a first-in-class investigational non-steroidal, selective mineralocorticoid receptor (MR) antagonist that demonstrated renal and cardiovascular benefits in patients with chronic kidney disease and type 2 diabetes • Finerenone specifically addresses MR overactivation, a key driver of disease progression • Despite guideline-directed therapies, patients with chronic kidney disease and type 2 diabetes remain at high risk of progression to kidney failure and cardiovascular events • Results from the FIDELIO-DKD study were simultaneously published in the New England Journal of Medicine
September 29, 2020
New data reinforce strong clinical profile of VITRAKVI® for patients of all ages with TRK Fusion Cancer including lung and thyroid tumours
• 78% overall response rate (ORR) and median progression-free survival (PFS) of more than 3 years (36.8 months) demonstrate extended benefit in updated data set of 175 adults and children • Majority of adverse events were grade 1 or 2; no new safety signals identified • Consistently high ORRs shown in lung and thyroid data subsets (71 and 75%, respectively), as well as long durability (estimated duration of response at 12 months of 88% and 95%, respectively) • Among patients from integrated dataset with brain metastases (n=14), ORR was 71%, and 57% in patients with lung cancer with brain metastases (n=7)